VENICE, ITALY — Personalized doses and slow tapering of semaglutide (Wegovy or Ozempic, Novo Nordisk) in patients who also follow a digital weight loss program can lead to maintenance of target weight up to 6 months later, show retrospective, real-world data. Lower doses were found to be just as effective as higher doses for weight …
